Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Kenji Izuhara, PhD"'
Autor:
Makiko Kido-Nakahara, MD, Daisuke Onozuka, PhD, Kenji Izuhara, PhD, Hidehisa Saeki, MD, Satoshi Nunomura, PhD, Motoi Takenaka, MD, Mai Matsumoto, MD, Yoko Kataoka, MD, Rai Fujimoto, MD, Sakae Kaneko, MD, Eishin Morita, MD, Akio Tanaka, MD, Michihiro Hide, MD, Tatsuro Okano, MD, Tomomitsu Miyagaki, MD, Natsuko Aoki, MD, Kimiko Nakajima, MD, Susumu Ichiyama, MD, Kyoko Tonomura, MD, Yukinobu Nakagawa, MD, Risa Tamagawa-Mineoka, MD, Koji Masuda, MD, Takuya Takeichi, MD, Masashi Akiyama, MD, Yozo Ishiuji, MD, Michie Katsuta, MD, Yuki Kinoshita, MD, Chiharu Tateishi, MD, Aya Yamamoto, MD, Akimichi Morita, MD, Haruna Matsuda-Hirose, MD, Yutaka Hatano, MD, Hiroshi Kawasaki, MD, Keiji Tanese, MD, Mamitaro Ohtsuki, MD, Koji Kamiya, MD, Yudai Kabata, MD, Riichiro Abe, MD, Hiroshi Mitsui, MD, Tatsuyoshi Kawamura, MD, Gaku Tsuji, MD, Masutaka Furue, MD, Norito Katoh, MD, Takeshi Nakahara, MD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 4, Pp 100317- (2024)
Background: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti–IL-4Rα antibody, have been developed in recent years. We need to predict which ag
Externí odkaz:
https://doaj.org/article/442b55c6ab214b19b904fcdf110b4187